Immunicum, a biopharmaceutical company in clinical stage development of a unique allogeneic, off-the-shelf, cell-based treatment for cancer is now establishing a presence in the BioVentureHub at AstraZeneca Gothenburg
Immunicum’s approach to activating a patient’s own immune system against cancer is based on important discoveries made by its scientific founder, Alex Karlsson-Parra. The company’s lead product, ilixadencel, is currently in clinical development in several solid tumor indications and has the potential to become a backbone component of modern cancer combination treatments. The company has an ongoing, global Phase II clinical trial in metastatic renal cell carcinoma with topline results expected in 2019.
Carlos de Sousa, CEO of Immunicum, commented, “Moving into the BioVentureHub will provide Immunicum’s Gothenburg team with the benefit of operating in a thriving, life-science-focused environment with high-quality infrastructure. We also like the mix of both established and earlier-stage biopharmaceutical companies and look forward to becoming a part of this exciting community.”
Magnus Björsne, CEO for AstraZeneca’s BioVentureHub added, “We’re excited to welcome Immunicum to the BioVentureHub. The company has come a long way on its journey of scientific innovation and will be a great addition to the vibrant life science ecosystem we are creating here. We look forward to collaborating closely with Carlos and his team, and to facilitate the development of new therapies that can benefit patients in the fight against cancer.”
For more information, please contact:
Carlos de Sousa, CEO, Immunicum, +46 8 732 8400, email@example.com
Jamie Smith, AstraZeneca BioVentureHub, +46 723-757507, Jamie.Smith1@astrazeneca.com
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com